title: The variation of CD4+CD25+ regulatory T cells in the periphery blood and tumor microenvironment of non-small cell lung cancer patients and the downregulation effects induced by CpG ODN.
abstract: The aim of the study was to observe the variation of CD4(+)CD25(+) regulatory T cells in periphery blood and tumor microenvironment of non-small cell lung cancer (NSCLC) patients and the effects of CpG ODN. The proportion of CD4(+)CD25(+) regulatory T cells, Foxp3 gene expression, levels of tumor growth factor-β (TGF-β) and immunoreactive fibronectin-γ (IFN-γ) in the periphery blood of 30 NSCLC patients and 30 healthy volunteers were compared. These indicators were compared before and after CpG ODN treatment. Foxp3 gene expression in the tumor microenvironment of NSCLC patients was also observed. The results showed CD4(+)CD25(+) regulatory T cell proportion, Foxp3 expression and TGF-β levels in the periphery blood of NSCLC patients were higher than those of healthy volunteers (p < 0.05), and these indicators of patients were significantly decreased after CpG ODN 2006 treatment (p < 0.05). Foxp3 expression in the metastatic lymph nodes was higher than that in the non-metastatic ones of NSCLC patients (p = 0.000). In conclusion, a rise in the proportion of CD4(+)CD25(+)Foxp3(+) regulatory T cells was demonstrated in the periphery blood and tumor microenvironments of NSCLC patients. CpG ODN 2006 downregulated the CD4(+)CD25(+)Foxp3(+) regulatory T cells proportion and TGF-β levels in the periphery blood of these patients.
authors: Department of Geriatrics, The Affiliated Zhongshan Hospital of Fudan University, Shanghai, 200032, China.
authors: Yan-Ying
authors: YY
authors: Wang
authors: Xiao-Ye
authors: XY
authors: He
authors: Ying-Yun
authors: YY
authors: Cai
authors: Zhi-Jun
authors: ZJ
authors: Wang
authors: Shao-Hua
authors: SH
authors: Lu
references: Cancer Res. 2002 Sep 15;62(18):5267-72
references: 12234995
references: J Immunother. 2006 May-Jun;29(3):233-40
references: 16699366
references: Nat Rev Cancer. 2005 Apr;5(4):263-74
references: 15776005
references: Immunol Rev. 2006 Aug;212:60-73
references: 16903906
references: Clin Cancer Res. 2003 Feb;9(2):606-12
references: 12576425
references: Immunol Rev. 2001 Aug;182:99-112
references: 11722627
references: Blood. 2003 Jun 15;101(12):5076-83
references: 12609834
references: Cytometry A. 2009 Dec;75(12):1040-50
references: 19845018
references: J Immunol. 1995 Aug 1;155(3):1151-64
references: 7636184
references: J Exp Med. 2001 Sep 3;194(5):629-44
references: 11535631
references: J Immunol. 2006 Feb 1;176(3):1582-7
references: 16424187
references: Clin Immunol. 2006 Jan;118(1):24-34
references: 16157508
references: J Exp Med. 2000 Jul 17;192(2):295-302
references: 10899916
references: Immunology. 2001 Aug;103(4):449-57
references: 11529935
references: Arch Immunol Ther Exp (Warsz). 2006 Nov-Dec;54(6):381-91
references: 17122882
references: J Exp Med. 2005 Mar 7;201(5):779-91
references: 15753211
references: Nat Med. 2004 Sep;10(9):942-9
references: 15322536
references: Eur J Immunol. 2004 Jan;34(1):251-62
references: 14971051
references: Cancer Immunol Immunother. 2004 Aug;53(8):697-704
references: 15034674